TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8725888

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy with leuprolide plus flutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finasteride treatment
Number of subjects: 0
Study: 1759789

Group type: EXPERIMENTAL
Intervention: Sustained release verapamil (240 mg/24 h)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Captopril (25 mg, 50 mg/24 h)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of sustained release verapamil + captopril
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sustained release verapamil
Number of subjects: 45

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 45
Study: 6349744

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy followed by chemotherapy using doxorubicin (Adriamycin) and 5-fluorouracil
Number of subjects: 129

Group type: COMPARATOR
Intervention: Radical radiotherapy alone
Number of subjects: 129
Study: 31332027

Group type: EXPERIMENTAL
Intervention: Weight loss diets (four different diets varying in macronutrient intake)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 264
Study: 29052691

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Multistep Medication Review (3MR)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Standard procedures (Control)
Number of subjects: 426
Study: 26076022

Group type: EXPERIMENTAL
Intervention: Chinese herbal formula Yishen Huazhuo decoction (YHD)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Donepezil hydrochloride (DH) 5 mg/day
Number of subjects: 144
Study: 25311881

Group type: EXPERIMENTAL
Intervention: Healthy corner store intervention
Number of subjects: 767

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 767
Study: 22173933

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/d for 1 week, then 10 mg twice daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 19574961

Group type: COMPARATOR
Intervention: Nitrendipine plus atenolol (N/A group)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nitrendipine, atenolol, and metformin (N/A/M group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Difference in BW before and after treatment between the two groups
Number of subjects: 94
Study: 17305301

Group type: EXPERIMENTAL
Intervention: Ethanol infusion (0.5 g ethanol/kg body weight/24 hours)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ethanol infusion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 15071723

Group type: EXPERIMENTAL
Intervention: Daily oral ibandronate (2.5 mg/day)
Number of subjects: 2946

Group type: EXPERIMENTAL
Intervention: Intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months)
Number of subjects: 2946

Group type: EXPERIMENTAL
Intervention: Daily and intermittent oral ibandronate
Number of subjects: 2946

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2946
Study: 11642557

Group type: EXPERIMENTAL
Intervention: Ariston pHc
Number of subjects: 31

Group type: COMPARATOR
Intervention: Solitaire I
Number of subjects: 31
Study: 9633845

Group type: EXPERIMENTAL
Intervention: Comprehensive surgical staging and disease removal alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0
Study: 7612732

Group type: EXPERIMENTAL
Intervention: CAPD (uninterrupted)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hemodialysis
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 68

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CAPD (predialysis)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CAPD (postdialysis)
Number of subjects: 68
Study: 2682123

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 971011

Group type: EXPERIMENTAL
Intervention: Nurse-administered protocol for headache management
Number of subjects: 203

Group type: COMPARATOR
Intervention: Physician-control group
Number of subjects: 203
Study: 31228203

Group type: EXPERIMENTAL
Intervention: 3 months of FOLFOX4 or CAPOX
Number of subjects: 1115

Group type: COMPARATOR
Intervention: 6 months of FOLFOX4 or CAPOX
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: 3 months of FOLFOX4
Number of subjects: 1115

Group type: COMPARATOR
Intervention: 6 months of FOLFOX4
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: 3 months of CAPOX
Number of subjects: 1115

Group type: COMPARATOR
Intervention: 6 months of CAPOX
Number of subjects: 1115
Study: 28575566

Group type: EXPERIMENTAL
Intervention: MTP plus IHHT (experimental group - EG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: MTP plus placebo (control group - CG)
Number of subjects: 34
Study: 26272871

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (DHA+EPA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 23265686

Group type: EXPERIMENTAL
Intervention: Positive verbal suggestion about pain being beneficial to muscles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative verbal suggestion about the aversive nature of the task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rimonabant (cannabinoid antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone and Rimonabant combined
Number of subjects: 0
Study: 21292702

Group type: EXPERIMENTAL
Intervention: Rich media job aids
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional job aids
Number of subjects: 50
Study: 19858385

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: RT and AST combined
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Increasing PSA velocity at recurrence
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Moderate to severe comorbidity score
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: PSA velocity at recurrence
Number of subjects: 206
Study: 16766329

Group type: EXPERIMENTAL
Intervention: M. vaccae vaccine (two subcutaneous injections 3 months apart)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15638973

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (Nasonex)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate (Betnesol)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Morning salivary cortisol (MSC)
Number of subjects: 48
Study: 11422585

Group type: EXPERIMENTAL
Intervention: Piezoelectric ultrasonic instrument
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Magnetostrictive ultrasonic instrument
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hand curette
Number of subjects: 30
Study: 9322981

Group type: COMPARATOR
Intervention: L-NAME (3.0 microg x kg(‐1) x min(‐1) for 90 minutes) after placebo pretreatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: L-NAME (3.0 microg x kg(‐1) x min(‐1) for 90 minutes) after losartan pretreatment (50 mg)
Number of subjects: 7
Study: 8486881

Group type: EXPERIMENTAL
Intervention: 200 mg of quinine taken at bedtime
Number of subjects: 16
Study: 3404455

Group type: EXPERIMENTAL
Intervention: LY-171883 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY-171883 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY-171883 400 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30391694

Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI; fructose) high-protein breakfast
Number of subjects: 19

Group type: COMPARATOR
Intervention: High glycemic index (GI; glucose) high-protein breakfast
Number of subjects: 19
Study: 28801422

Group type: EXPERIMENTAL
Intervention: Qualitative semi-structured interviews with trial site staff
Number of subjects: 11
Study: 25616671

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 0
Study: 24334179

Group type: EXPERIMENTAL
Intervention: Crofelemer 125 mg twice daily
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 21365028

Group type: EXPERIMENTAL
Intervention: Buccal plate preservation (BPP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 16
Study: 18390891

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combined therapy (Benazepril and Valsartan)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 156
Study: 21843712

Group type: EXPERIMENTAL
Intervention: Serum Amyloid A (SAA)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Serum Amyloid A (SAA), C-reactive protein (CRP), Procalcitonin (PCT)
Number of subjects: 152
Study: 16186435

Group type: EXPERIMENTAL
Intervention: Duplex surveillance
Number of subjects: 594

Group type: COMPARATOR
Intervention: Clinical surveillance
Number of subjects: 594
Study: 11833550

Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis) Turbuhaler plus Budesonide (Pulmicort) Turbuhaler
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort) Turbuhaler alone
Number of subjects: 338

Group type: COMPARATOR
Intervention: Conventional non-corticosteroid therapy
Number of subjects: 338
Study: 11475742

Group type: EXPERIMENTAL
Intervention: Garlicin 60 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nitroglycerin 5 mg
Number of subjects: 55
Study: 7652690

Group type: EXPERIMENTAL
Intervention: PAPU (150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2547858

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 200 micrograms twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nedocromil sodium (NED) 4 mg twice daily
Number of subjects: 39
Study: 22421

Group type: EXPERIMENTAL
Intervention: 18-hydroxy-11-deoxycorticosterone (120 microgram intravenously in 1 h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aldosterone (80 microgram)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Glucose (50 g/l; control)
Number of subjects: 7
Study: 773198

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (2 gm, approximately 30 mg/kg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 28614163

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval exercise (HIIE): 10 × 60 seconds at 90% of maximal velocity (MV) with 60 seconds of active recovery at 30% of MV
Number of subjects: 15

Group type: COMPARATOR
Intervention: Continuous exercise (CE): 20 minutes at 60% of maximal velocity (MV)
Number of subjects: 15
Study: 29383953

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Face-to-face group cognitive behavioural therapy (GCBT)
Number of subjects: 84
Study: 27106105

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 989

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study: 24453130

Group type: COMPARATOR
Intervention: 800 mg of Calcium (Ca)
Number of subjects: 300

Group type: COMPARATOR
Intervention: 800 mg of Calcium with 3.6 g of short-chain fructo-oligosaccharides (CaFOS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: maltodextrin
Number of subjects: 300

Group type: COMPARATOR
Intervention: CaFOS in women with osteopenia
Number of subjects: 300
Study: 22704364

Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 21049601

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MP) and mouse nerve growth factor (mNGF) for injection
Number of subjects: 43

Group type: COMPARATOR
Intervention: Methylprednisolone sodium succinate (MP) only
Number of subjects: 43
Study: 17382027

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small molecule inhibitors targeting VEGF receptor and tyrosine kinase receptor combined with standard chemotherapy
Number of subjects: 0
Study: 15126020

Group type: EXPERIMENTAL
Intervention: Nutritional supplements (lemon-flavored cod liver oil and children's multivitamin-mineral with selenium)
Number of subjects: 4
Study: 11641299

Group type: EXPERIMENTAL
Intervention: Intralipid and heparin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline and heparin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline with intralipid and heparin
Number of subjects: 15
Study: 9825068

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 227

Group type: COMPARATOR
Intervention: Cloxacillin
Number of subjects: 227
Study: 8129390

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CDDP 75 mg/m2 i.v. day 1 or 20 mg/m2 i.v. day 1, 2, 4, 5; MMC 10 mg/m2 i.v. day 1; etoposide 50 mg/body i.v. day 3, 4, 5; 5'-DFUR 2,100 mg/body po 4 day/week)
Number of subjects: 7
Study: 2530998

Group type: EXPERIMENTAL
Intervention: mivacurium 0.15 mg kg‐1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: mivacurium 0.20 mg kg‐1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: mivacurium 0.25 mg kg‐1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: suxamethonium 1.0 mg kg‐1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: atracurium 0.5 mg kg‐1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: mivacurium
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: atracurium
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: mivacurium (higher doses)
Number of subjects: 41
Study: 1173736

Group type: EXPERIMENTAL
Intervention: Proprietary milk with lactase preparation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Lactose-free milk
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Proprietary milk
Number of subjects: 3
Study: 31397943

Group type: EXPERIMENTAL
Intervention: bleselumab 50 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: bleselumab 100 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: bleselumab 200 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: bleselumab 500 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 29710295

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin, 100 mg 3 times a day for 5 days (n=255)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Fosfomycin, single 3-g dose (n=258)
Number of subjects: 513
Study: 28063345

Group type: EXPERIMENTAL
Intervention: VPAN program (Physical Activity and Nutrition program)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Education sessions (part of the VPAN program)
Number of subjects: 214
Study: 26316344

Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator plus endovascular therapy (Solitaire device)
Number of subjects: 195

Group type: COMPARATOR
Intervention: tissue-type plasminogen activator alone
Number of subjects: 195
Study: 23597719

Group type: EXPERIMENTAL
Intervention: RV3-BB rotavirus vaccine (8.3×10(6)FFU/mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21172479

Group type: EXPERIMENTAL
Intervention: Skeletonized left internal mammary artery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pedicled left internal mammary artery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pedicled harvesting
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Postoperative echocardiographic results and clinical and angiographic outcomes
Number of subjects: 200
Study: 18296987

Group type: EXPERIMENTAL
Intervention: Pedometer (Walk4Life LS‐7010)
Number of subjects: 102
Study: 16553812

Group type: EXPERIMENTAL
Intervention: MenC/P64k vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercial polysaccharide vaccine AC
Number of subjects: 20
Study: 12393737

Group type: EXPERIMENTAL
Intervention: Home care after SCT
Number of subjects: 90
Study: 10354806

Group type: EXPERIMENTAL
Intervention: Type A individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Type B individuals
Number of subjects: 0
Study: 8834630

Group type: EXPERIMENTAL
Intervention: Peripheral blood PMNs at rest
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Peripheral blood PMNs stimulated
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (clinically healthy persons) at rest
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (clinically healthy persons) stimulated
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coronary sinus PMNs at rest
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coronary sinus PMNs stimulated
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: H2O2 generation by rest PMNs from coronary sinus
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: H2O2 generation by PMA stimulated PMNs
Number of subjects: 24
Study: 1980911

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5ASA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Salazosulphapyridine (SASP)
Number of subjects: 86
Study: 7369159

Group type: EXPERIMENTAL
Intervention: Zinfandel wine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aqueous ethanol solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dealcoholized Zinfandel wine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 6
Study: 31392363

Group type: COMPARATOR
Intervention: Vaginal estrogen treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen-only or combination systemic HRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local estrogen treatment (LET)
Number of subjects: 0
Study: 30053284

Group type: EXPERIMENTAL
Intervention: Slimming World (SW) program with low energy-dense (LED) meals
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard Care (SC) program with high energy-dense (HED) meals
Number of subjects: 96
Study: 28069521

Group type: EXPERIMENTAL
Intervention: Simplified Faces Pain Scale (S-FPS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Simplified Concrete Ordinal Scale (S-COS)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Faces Pain Scale-Revised (FPS-R)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Observation (Face Legs Activity Cry Consolability)
Number of subjects: 180
Study: 26321708

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 43

Group type: COMPARATOR
Intervention: HAIC
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sorafenib therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Longer treatment period of sorafenib
Number of subjects: 43
Study: 23909782

Group type: EXPERIMENTAL
Intervention: Corneal inlay removal
Number of subjects: 10
Study: 21370962

Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention (SDMI)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Treatment decision-making as usual (Control)
Number of subjects: 212
Study: 18694479

Group type: EXPERIMENTAL
Intervention: Individual counselling on physical activity and diet at five routine visits to a PHN and supervised group exercise until 37 weeks' gestation or ten months postpartum
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control clinics continued their usual care
Number of subjects: 132
Study: 16552744

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery (da Vinci Surgical System)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard laparoscopic fundoplication
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 12746751

Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 4

Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 4
Study: 10902993

Group type: EXPERIMENTAL
Intervention: Energy supplement (E) = 1171 kJ + 12 mg iron
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Micronutrient supplement (M) = 12 mg iron + 209 kJ
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control (S) = 104 kJ
Number of subjects: 136
Study: 9151070

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Xylitol-sorbitol chewing gum
Number of subjects: 37

Group type: COMPARATOR
Intervention: Unsweetened chewing gum base (Control)
Number of subjects: 37
Study: 7963139

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (100 or 600 mg daily for 58 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro studies of ascorbic acid
Number of subjects: 0
Study: 3597142

Group type: EXPERIMENTAL
Intervention: Pelvic irradiation followed by a prostatic boost
Number of subjects: 453

Group type: COMPARATOR
Intervention: Prostate irradiation only
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Total doses to the prostate of more than 7000 cGy
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: AP/PA irradiation of the pelvic lymphatics
Number of subjects: 453
Study: 29109047

Group type: EXPERIMENTAL
Intervention: Anapen autoinjector
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prefilled syringe (25.4-mm needle)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anapen autoinjector in overweight women
Number of subjects: 30
Study: 26933849

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles
Number of subjects: 692

Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles among patients not receiving bevacizumab
Number of subjects: 692

Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles among patients not receiving bevacizumab
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles among patients receiving bevacizumab
Number of subjects: 692

Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles among patients receiving bevacizumab
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel
Number of subjects: 692